12,841 resources
Start Prev Rows 11800 - 12000 Next
| Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Auth | Source(s) |
|---|---|---|---|---|---|---|---|---|---|
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3211 | Material exposure type | active | 2009-01 | sct oid | |||
| hl7.fhir.us.mcode | R4 | mcode-hypereosinophilic-syndrome-disorder-vs | Specific Diagnosis of Cancer Value Set | active | 4 | cic | 2025-02 | hl7 | sct icd |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7732 | Infection Type (RIBD) | active | 2018-01 | sct tho oid | |||
| hl7.fhir.us.davinci-drug-formulary | R4 | InsuranceItemTypeVS | Insurance item type | trial-use | phx | 2025-02 | hl7 | fhir | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3133 | Live Birth Outcome (Rubella) | active | 2008-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.1006 | Type of Long Term Care Facility | active | 2019-01 | tho oid | |||
| hl7.fhir.us.mcode | R4 | mcode-melanoma-in-situ-disorder-vs | Melanoma In-Situ Disorder Value Set | active | 4 | cic | 2025-02 | hl7 | sct icd |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3135 | Non-Live Birth Outcome (VPD) | active | 2008-01 | sct | |||
| hl7.fhir.us.mcode | R4 | mcode-primary-malignant-neoplasm-disorder-vs | Primary Malignant Neoplasm Disorder Value Set | active | 4 | cic | 2025-02 | hl7 | sct icd |
| hl7.fhir.us.mcode | R4 | mcode-primary-cancer-disorder-vs | Primary Cancer Disorder Value Set | active | 4 | cic | 2025-02 | hl7 | fhir |
| hl7.fhir.us.mcode | R4 | mcode-cancer-staging-prognostic-factor-type-vs | Cancer Staging Prognostic Factors Types | active | cic | 2025-02 | hl7 | sct | |
| hl7.fhir.us.mcode | R4 | mcode-secondary-cancer-disorder-vs | Secondary Cancer Disorder Value Set | active | 4 | cic | 2025-02 | hl7 | sct icd |
| hl7.fhir.us.davinci-pas | R4 | PASSupportingInfoType | PAS Supporting Info Type Value Set | trial-use | 3 | fm | 2025-07 | hl7 | fhir |
| us.nlm.vsac | R4 | 2.16.840.1.113883.10.20.22.5.300 | Transmission Based Precaution Types | active | 2024-06 | hl7 | sct | ||
| hl7.cda.us.eyecare | R5 | AidToVisionCodes | Aid to Vision Codes | draft | 2024-02 | hl7 | sct | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7941 | Job Setting (COVID-19) | active | 2020-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7647 | Typhoid Paratyphoid Serotype (FDD) | active | 2017-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3111 | Typhoid Signs Symptoms (FDD) | active | 2008-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3590 | Pulse Oximetry Unit | active | 2010-01 | ucum | |||
| fhir.virtually.healthcare | R4 | UKCorrelationIdentifier | UK Common Resource Identifiers | draft | 2025-07 | hl7 | internal | ||
| fhir.virtually.healthcare | R4 | UKNationalIdentifiers | UK National Insurance Identifiers | draft | 2025-07 | hl7 | internal | ||
| fhir.virtually.healthcare | R4 | ProfessionalLicense | UK Professional License | draft | 2025-07 | hl7 | internal | ||
| fhir.virtually.healthcare | R4 | StaffNumber | UK StaffNumber | draft | 2025-07 | hl7 | internal | ||
| hl7.fhir.us.davinci-pct | R4 | PCTTaskAttachmentContentType | US Claim DRG Codes | trial-use | fm | 2025-06 | hl7 | fhir | |
| hl7.fhir.us.davinci-pct | R4 | USClaimDRGCodes | US Claim DRG Codes | trial-use | fm | 2025-06 | hl7 | cms | |
| fhir.cdc.opioid-cds-r4 | R4 | condition-us-core-health-concern-category | US Core Health Concern Condition Category | active | 2023-05 | hl7 | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.973 | City | active | 2020-01 | oid | |||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1196.4469 | Cabotegravir Injectable Products | active | 2024-05 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1196.4470 | Emtricitabine oral for HIV PrEP | active | 2024-05 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1196.4474 | HIV Laboratory Based Tests | active | 2024-05 | hl7 | loinc | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3322 | Underlying Conditions (IPD) | active | 2010-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7681 | Underlying Condition (RIBD) | active | 2018-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7947 | Risk Factor (COVID-19) | active | 2020-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3112 | Underlying Conditions | active | 2008-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3402 | Age Unit (Syndromic Surveillance) | active | 2011-01 | ucum tho | |||
| hl7.fhir.us.codex-radiation-therapy | R4 | codexrt-image-guided-radiotherapy-energy-unit-vs | Image Guided Radiotherapy Energy Unit Value Set | draft | cgp | 2025-02 | hl7 | ucum | |
| hl7.fhir.us.codex-radiation-therapy | R4 | codexrt-radiotherapy-energy-unit-vs | Radiotherapy Energy Unit Value Set | draft | cgp | 2025-02 | hl7 | ucum | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7667 | Eosinophil Units | active | 2018-01 | ucum | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.891 | Height Unit | active | 2008-01 | ucum | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7372 | Time Units (NCHS) | active | 2015-01 | ucum tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.879 | Weight Unit | active | 2008-01 | ucum | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7906 | Test result units (ARLN) | active | 2019-01 | ucum | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.838 | Units of Measure | active | 2015-01 | ucum | |||
| hl7.fhir.us.pq-cmc-fda | R5 | pqcmc-non-percentage-units | Non-Percentage Units | trial-use | 2 | brr | 2025-07 | hl7 | fhir |
| hl7.fhir.us.pq-cmc-fda | R5 | pqcmc-percentage-units | Percentage Units | trial-use | 2 | brr | 2025-07 | hl7 | ucum |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.920 | Blood Pressure Unit | active | 2008-01 | ucum | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.878 | Age unit | active | 2015-01 | ucum tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.919 | Temperature Unit | active | 2008-01 | ucum | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7819 | Unit of Measure (TB) | active | 2018-01 | ucum | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7451 | Type of Testing at CDC (VZ) | active | 2015-12 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7452 | Age Unit (NND) | active | 2015-12 | ucum tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7453 | Body Region(s) of Rash | active | 2018-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7454 | Character of Lesions | active | 2015-12 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7474 | Type of Complication (VZ) | active | 2017-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7456 | Lab Test Type (Varicella) | active | 2018-01 | oid loinc | |||
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.41 | Tobacco Use | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1032.90 | Gestational Diabetes | active | 2024-06 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.1921 | Beta Blocker Therapy Ingredient | active | 2024-02 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1493 | Beta Blocker Therapy Ingredient | active | 2017-05 | hl7 | vsac | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.822 | Referral Priority (HL7) | active | 2008-01 | tho | |||
| fhir.cdc.opioid-cds-r4 | R4 | cocaine-urine-drug-screening-tests | Cocaine urine drug screening tests | active | 2023-05 | hl7 | |||
| fhir.cdc.opioid-cds-r4 | R4 | fentanyl-type-urine-drug-screening-tests | Fentanyl-type urine drug screening tests | active | 2023-05 | hl7 | |||
| fhir.cdc.opioid-cds-r4 | R4 | opiate-specific-urine-drug-screening-tests | Opiate specific urine drug screening tests | active | 2023-05 | hl7 | |||
| fhir.cdc.opioid-cds-r4 | R4 | phencyclidine-urine-drug-screening-tests | Phencyclidine urine drug screening tests | active | 2023-05 | hl7 | |||
| fhir.cdc.opioid-cds-r4 | R4 | synthetic-opioid-urine-drug-screening-tests | Synthetic opioid urine drug screening tests | active | 2023-05 | hl7 | |||
| fhir.cdc.opioid-cds-r4 | R4 | all-urine-drug-screening-tests | All urine drug screening tests | active | 2023-11 | hl7 | internal | ||
| fhir.cdc.opioid-cds-r4 | R4 | methadone-urine-drug-screening-tests | Methadone urine drug screening tests | active | 2023-05 | hl7 | loinc | ||
| fhir.cdc.opioid-cds-r4 | R4 | amphetamine-urine-drug-screening-tests | Amphetamine-class drugs and metabolite urine tests | active | 2023-05 | hl7 | loinc | ||
| hl7.fhir.us.vdor | R4 | vdor-use-of-prescription-morphine-vs | VDOR Use of Prescription Morphine | informative | pher | 2025-06 | hl7 | fhir | |
| signal.core.r4 | R4 | contact-point-use | ContactPointUse | draft | 0 | fhir | 2019-10 | hl7 | fhir |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.2.11.7101 | VPD Reason for Study | active | 2013-01 | oid | |||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.1444.3.227 | Neoplasm of Brain | active | 2024-07 | hl7 | icd | ||
| hl7.fhir.us.carin-bb | R4 | C4BBAdjudicationCategoryDiscriminator | C4BB Adjudication Category Discriminator Value Set | trial-use | fm | 2025-02 | hl7 | fhir | |
| hl7.fhir.us.davinci-pdex | R4 | PDexAdjudicationCategoryDiscriminator | PDex Adjudication Category Discriminator | informative | fm | 2025-06 | hl7 | fhir | |
| hl7.fhir.us.carin-bb | R4 | C4BBSupportingInfoType | C4BB SupportingInfo Type Value Set | trial-use | fm | 2025-02 | hl7 | fhir | |
| hl7.fhir.us.davinci-pdex | R4 | PDexSupportingInfoType | PDex SupportingInfo Type | informative | fm | 2025-06 | hl7 | fhir | |
| hl7.fhir.us.carin-bb | R4 | C4BBTotalCategoryDiscriminator | C4BB Total Category Discriminator Value Set | trial-use | fm | 2025-02 | hl7 | fhir | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7367 | Exposure Time Frame (NND) | active | 2015-01 | oid | |||
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.44 | Mental and Functional Status Response | active | 2024-06 | hl7 | sct | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.5015 | Role (PHLIP) | active | 2011-01 | tho oid | |||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.1444.5.244 | Anthracycline Injectable | active | 2024-10 | hl7 | vsac | ||
| hl7.fhir.us.core | R4 | us-core-clinical-result-observation-category | US Core Clinical Result Observation Category | trial-use | 3 | cgp | 2023-04 | hl7 | tho |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7378 | Death Reporting Name Type Code (NCHS) | active | 2016-01 | tho | |||
| us.nlm.vsac | R4 | 2.16.840.1.113883.1.11.11610 | x_ActRelationshipDocument | active | 2024-06 | hl7 | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.1.11.16926 | HL7 BasicConfidentialityKind | active | 2024-06 | hl7 | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1029.67 | Other Health Care Facility | active | 2025-05 | hl7 | sct | ||
| us.cdc.phinvads | R4 | 1.3.6.1.4.1.19376.1.7.3.1.1.15.2.2 | JCIH-EHDI Outpatient Encounter | active | 2010-01 | tho | |||
| hl7.fhir.us.pacio-pfe | R4 | pfe-survey-category-vs | Personal Functioning and Engagement Survey Value Set | trial-use | 3 | pc | 2025-07 | hl7 | tho |
| hl7.fhir.us.icsr-ae-reporting | R4 | ICSRAESeriousness | ICSR Top-Level Seriousness | draft | 2023-08 | hl7 | tho | ||
| signal.core.r4 | R4 | data-absent-reason | DataAbsentReason | normative | 5 | fhir | 2019-10 | hl7 | tho |
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1240.4 | Asked Declined Data Absent Reason | active | 2023-06 | hl7 | tho | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7442 | Death Reporting Event Type (NCHS) | active | 2016-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3363 | Patient Class (IIS) | active | 2010-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3365 | Relationship (IIS) | active | 2010-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3366 | Financial Class (IIS) | active | 2010-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3372 | Identifier Type (IIS) | active | 2010-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3373 | Organizational Name Type (IIS) | active | 2010-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3374 | Query Response Status (IIS) | active | 2018-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3384 | Publicity Code (IIS) | active | 2010-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3377 | Immunization Registry Status (HL7) | active | 2010-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3378 | Immunization Registry Status (IIS) | active | 2010-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3379 | Query Name (IIS) | active | 2010-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.814 | Religion (HL7) | active | 2008-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.816 | Route of Administration (HL7) | active | 2008-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.812 | Production Class (HL7) | active | 2008-01 | tho | |||
| signal.core.r4 | R4 | questionnaire-dacods-admission-route-of-administration | Questionnaire DACODS Admission Route Of Administration | draft | 1 | pa | hl7 | ||
| signal.core.r4 | R4 | questionnaire-dacods-discharge-route-of-administration | Questionnaire DACODS Discharge Route Of Administration | draft | 1 | pa | hl7 | ||
| fhir.virtually.healthcare | R4 | VHConditionCode | VH Condition Code | draft | 2025-07 | hl7 | sct | ||
| fhir.virtually.healthcare | R4 | VHImmunisationCode | VH Immunisation Code | draft | 2025-07 | hl7 | sct | ||
| fhir.virtually.healthcare | R4 | VHMedicationCode | VH Medication Code | draft | 2025-07 | hl7 | sct | ||
| fhir.virtually.healthcare | R4 | VHObservationCode | VH Observation Code | draft | 2025-07 | hl7 | sct | ||
| fhir.virtually.healthcare | R4 | VHObservationValueCode | VH Observation Value Code | draft | 2025-07 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.9 | ER Test for Orserdu | active | 2023-08 | hl7 | ncit | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.185 | Spinal Surgery | active | 2024-06 | hl7 | cms | ||
| fhir.giis | R4 | VaccinationSiteVS | Vaccination body site | draft | 2025-07 | hl7 | internal | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7689 | Vaccination Information Source (RIBD) | active | 2018-01 | sct tho oid | |||
| fhir.giis | R4 | VaccinationReasonVS | Vaccination reason | draft | 2025-07 | hl7 | internal | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.934 | Vaccines administered (CVX) | active | 2022-01 | cvx | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3410 | Vaccine Not Given Reasons (NETSS) | active | 2011-01 | sct tho oid | |||
| fhir.giis | R4 | VaccineVS | Vaccine codes | draft | 2025-07 | hl7 | internal | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7646 | Vaccine Received (FDD) | active | 2017-01 | cvx | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.1049 | Substance Administered (CRA) | active | 2008-01 | cvx | |||
| hl7.fhir.us.registry-protocols | R4 | NCDRErrorsVS | NCDRErrorsVS | active | cic | 2023-11 | hl7 | fhir | |
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1489 | ACE Inhibitor or ARB or ARNI Ingredient | active | 2023-02 | hl7 | vsac | ||
| hl7.fhir.us.davinci-pct | R4 | PCTAdjudicationCategoryVS | PCT GFE Item Adjudication Value Set | trial-use | fm | 2025-06 | hl7 | fhir tho | |
| us.nlm.vsac | R4 | 2.16.840.1.113883.10.20.22.5.305 | Microbiology and Antimicrobial Susceptibility Tests | active | 2024-06 | hl7 | loinc | ||
| hl7.fhir.us.directory-query | R4 | OrganizationAffiliationRoleVS | OrganizationAffiliation Roles | active | 2022-12 | hl7 | fhir | ||
| hl7.fhir.us.davinci-pdex-plan-net | R4 | OrganizationAffiliationRoleVS | OrganizationAffiliation Roles | trial-use | fm | 2025-02 | hl7 | fhir | |
| hl7.fhir.us.ndh | R4 | OrganizationAffiliationRoleVS | OrganizationAffiliation Roles | trial-use | pa | 2025-07 | hl7 | fhir tho | |
| hl7.fhir.us.directory-attestation | R4 | OrganizationAffiliationRoleVS | OrganizationAffiliation Roles | active | 2022-12 | hl7 | fhir | ||
| hl7.fhir.us.qicore | R4 | qicore-present-on-admission | QICore Present On Admission Codes | trial-use | 4 | cqi | 2021-05 | hl7 | cms |
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.37 | TargetSite Qualifiers | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1099.29 | Allergy Clinical Status | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.1.11.1 | Administrative Gender (HL7 V3) | active | 2024-06 | hl7 | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.1.11.20.2 | Advance Directive Type Code | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.88.12.3221.8.9 | Body Site Value Set | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.1.11.18877 | Coverage Role Type Value Set | active | 2024-06 | hl7 | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.26 | EntityPersonNamePartQualifier | active | 2024-06 | hl7 | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.1.11.12212 | Marital Status | active | 2024-06 | hl7 | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.33 | INDRoleclassCodes | active | 2024-06 | hl7 | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.88.12.80.64 | Medication Fill Status | active | 2024-06 | hl7 | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.18 | MoodCodeEvnInt | active | 2024-06 | hl7 | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.25 | Planned moodCode (Observation) | active | 2024-06 | hl7 | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.24 | Planned moodCode (SubstanceAdministration/Supply) | active | 2024-06 | hl7 | tho | ||
| fhir.kenyaPSIG | R4 | medication-vs | Medication Value Set | draft | 2025-07 | hl7 | sct | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3392 | Value Type (IIS) | active | 2018-01 | tho | |||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1108.101 | Myocardial Infarction | active | 2024-02 | hl7 | vsac | ||
| hl7.fhir.us.breastcancer | R3 | oncology-HER2FISHMethodVS | BC HER2FISHMethodVS ValueSet | draft | 2018-08 | hl7 | sct | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.8001 | Time of Day (CDC) | active | 2020-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7265 | Duration Unit | active | 2020-01 | ucum tho | |||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1213.110 | Corticosteroid Ingredients and Risk of GI Bleeding | active | 2023-12 | hl7 | rx | ||
| hl7.fhir.us.breastcancer | R3 | oncology-HER2byIHCScoreVS | BC HER2byIHCScoreVS ValueSet | draft | 2018-08 | hl7 | loinc | ||
| hl7.fhir.us.breastcancer | R3 | shr-core-PositiveNegativeVS | BC PositiveNegativeVS ValueSet | draft | 2018-08 | hl7 | sct | ||
| hl7.fhir.us.breastcancer | R3 | shr-core-PositiveNegativeIndeterminateVS | BC PositiveNegativeIndeterminateVS ValueSet | draft | 2018-08 | hl7 | sct | ||
| hl7.fhir.us.mcode | R4 | mcode-lansky-play-performance-vs | Lansky Play Performance Status VS | active | cic | 2025-02 | hl7 | ncit | |
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.249 | pralsetinib | active | 2024-06 | hl7 | rx | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7777 | Healthcare Service Location (Syndromic) | active | 2020-01 | cdc | |||
| hl7.fhir.us.physical-activity | R4 | pa-goal-target-measure | PA Goal Target Measure Codes | informative | pc | 2024-03 | hl7 | fhir | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.954 | BioSense Observations | active | 2008-01 | oid loinc | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7333 | Timing of Maternal Treatment (NND) | active | 2015-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3045 | Microorganism (Hepatitis) | active | 2016-01 | sct | |||
| hl7.fhir.us.odh | R4 | obf-datatype-YesNoVS | Yes No VS | draft | 2020-01 | hl7 | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.6062 | Observation Result Status Interpretation Codes | active | 2012-01 | tho | |||
| hl7.fhir.us.pq-cmc-fda | R5 | cmc-comp-section-types-vs | eCTD sections Terminology | trial-use | 2 | brr | 2025-07 | hl7 | tho |
| hl7.fhir.us.pco | R4 | pco-goal-domain-categories | PCO Goal Domain Categories | draft | 2 | pc | 2025-03 | hl7 | fhir |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7911 | Clinical sample or isolate (ARLN) | active | 2019-01 | sct oid | |||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1166.22 | Pregnancy Intention | active | 2023-08 | hl7 | sct | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7228 | CSF WBC Protein Result (NND) | active | 2020-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7950 | Yes No Unknown NA (NND) | active | 2020-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7486 | Yes No Not Applicable (NCHS) | active | 2017-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.888 | Yes No Unknown (YNU) | active | 2008-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7193 | YNRD (CDC) | active | 2020-01 | tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.819 | Yes No Indicator (HL7) | active | 2018-12 | tho | |||
| fhir.nw-gmsa.nhs.uk | R4 | RequestPriority | Request Priority | draft | 2025-04 | hl7 | fhir | ||
| fhir.nw-gmsa.nhs.uk | R4 | YN | Yes/No | draft | 2025-04 | hl7 | loinc | ||
| fhir.nw-gmsa.nhs.uk | R4 | YNU | Yes/No/Unknown | draft | 2025-04 | hl7 | loinc | ||
| fhir.kenyaPSIG | R4 | gender-vs | Gender ValueSet | draft | 2025-07 | hl7 | sct | ||
| fhir.tx.support.r4 | R4 | MDC-dimension | MDC Unit of Measurement | active | hl7 | iso | |||
| fhir.tx.support.r4 | R4 | MDC-metric | MDC Metric nomenclature | active | hl7 | iso | |||
| fhir.tx.support.r4 | R4 | MDC-object | MDC Object infrastructure and Device nomenclature | active | hl7 | iso | |||
| fhir.tx.support.r4 | R4 | MDC | MDC Nomenclature | active | hl7 | iso | |||
| fhir.tx.support.r4 | R4 | MDC-partition | MDC Partition codes | active | hl7 | iso | |||
| hl7.fhir.us.registry-protocols | R4 | HealthInsurancePaymentSource | Health Insurance Payment Source | active | cic | 2023-11 | hl7 | fhir | |
| fhir.dgmc | R4 | hospitals-uris-cml-answer | Hospitals Uris Chameleon Answer | draft | 2024-07 | hl7 | |||
| fhir.dgmc | R4 | hospitals-uris-cml-request | Hospitals Uris Chameleon Request | draft | 2024-07 | hl7 | |||
| fhir.dgmc | R4 | hospitals-uris-cml-medical-record | Hospitals Uris Chameleon Medical Record | draft | 2024-07 | hl7 | |||
| fhir.dgmc | R4 | hospitals-uris-cml-pat-int | Hospitals Uris Chameleon Patient Internal | draft | 2024-07 | hl7 | |||
| fhir.dgmc | R4 | hospitals-uris-Enc-Diet-Pref | Hospitals Uris Encounter Diet Preference | draft | 2024-07 | hl7 | |||
| fhir.dgmc | R4 | hospitals-uris-Nmr-Case-Num | Hospitals Uris Namer Case Number | draft | 2024-07 | hl7 | |||
| fhir.dgmc | R4 | hospitals-uris-nmr-pat-int | Hospitals Uris Namer Patient Internal | draft | 2024-07 | hl7 | |||
| fhir.dgmc | R4 | hospitals-uris-nmr-pat-tmp | Hospitals Uris Namer Patient Temp | draft | 2024-07 | hl7 | |||
| fhir.dgmc | R4 | hospitals-uris-Nmr-To-Cml-Ident | Hospitals Uris Maner to Chameleon Identifier | draft | 2024-07 | hl7 | |||
| fhir.org.nz.ig.base | R4 | acc-patient-occupation-valueset | ACC Patient Occupation | active | 2025-06 | hl7 | |||
| hl7.fhir.us.mcode | R4 | mcode-history-of-metastatic-malignant-neoplasm-vs | History of Metastatic Malignant Neoplasm Value Set | active | cic | 2025-02 | hl7 | sct | |
| hl7.fhir.us.breastcancer | R3 | oncology-LymphNodeMobilityVS | BC LymphNodeMobilityVS ValueSet | draft | 2018-08 | hl7 | sct | ||
| hl7.fhir.us.mcode | R4 | mcode-tnm-stage-group-max-vs | TNM Stage Group Maximum Value Set | active | cic | 2025-02 | hl7 | fhir | |
| hl7.fhir.us.mcode | R4 | mcode-figo-stage-value-vs | FIGO Stage Value Set | active | cic | 2025-02 | hl7 | ncit | |
| hl7.fhir.us.mcode | R4 | mcode-tnm-distant-metastases-category-max-vs | TNM Distant Metastases Maximum Value Set | active | cic | 2025-02 | hl7 | fhir | |
| hl7.fhir.us.mcode | R4 | mcode-tnm-primary-tumor-category-max-vs | TNM Primary Tumor Maximum Value Set | active | cic | 2025-02 | hl7 | fhir | |
| hl7.fhir.us.mcode | R4 | mcode-tnm-regional-nodes-category-max-vs | TNM Regional Nodes Maximum Value Set | active | cic | 2025-02 | hl7 | fhir |
FHIR